Sign up USA
Proactive Investors - Run By Investors For Investors

Celldex's triple-negative breast cancer drug fails in clinical trial; shares plummet

The company plans to discontinue its research into glembatumumab vedotin
Picture of a woman undergoing chemotherapy
The company is now shaking up its pipeline, which consists of five drug candidates

Shares of Celldex Therapeutics Inc (NASDAQ:CLDX)  plunged after the company said that the phase 2b trial for its treatment of triple-negative breast cancer has failed.

The stock shed 64% to trade at US$0.78 in early afternoon trading.

The company reported that its drug candidate -- glembatumumab vedotin known as glemba -- which was taken by patients with metastatic triple-negative breast cancer -- did not meet its primary end point of improving progression-free survival in its phase 2b clinical trial. Celldex also said that there is no advantage for glemba in key secondary endpoints.

The biopharmaceutical firm plans to discontinue its glemba program and it is shaking up its pipeline, which consists of five drug candidates that are involved in ongoing clinical studies.

“Triple-negative breat cancer is a very difficult disease to treat, and we are extremely disappointed for patients that the METRIC study was not successful,” said Anthony Marucci, the co-founder and chief executive officer of Celldex. “In line with this, we are evaluating our operational and workforce needs to extend our financial resources and direct them to continued pipeline advancement. Once we solidify these plans, we intend to update investors.”

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

Apollo 11
February 22 2018
Immersive VR, a technology company focused on the education space, was the first company Sure backed
August 15 2018
Milan Patel, dotdigital’s chief executive officer said: "This year reflects substantial progress against the company's strategic aims in accelerating our platform capabilities into the omnichannel space, continuing to innovate our product, growing geographically and deepening our relationships with our strategic partners”
September 19 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use